Strides Arcolab receives US FDA approval for ifosfamide inj

Onco Therapies Limited, a wholly owned subsidiary of Strides Arcolab Limited (Strides) has received ANDA approval for Ifosfamide Injection 50 mg/ mL packaged in 1 gram/ 20 mL and 3 grams/ 60 mL Single-dose vials.

According to IMS data, the US market for generic Ifosfamide is approximately $ 15 million.

Ifosfamide is part of the oncology portfolio licensed to Pfizer for the US market and the product is available for immediate launch. Ifosfamide is a  chemotherapy drug that is usually  used to treat sarcoma, testicular cancer and some types of lymphomas. Occasionally, it may be used to treat other types of cancer.

EP News Bureau

Comments (0)
Add Comment